

Ganglioside Antibody Markers

Accreditation Status:	UKAS Schedule of Accreditation								
Date Scheme started:	2014								
Clinical Applicability:	Diagnosis of neuropathy syndromes								
Analytes:	IgG, IgM, IgG/IgM: GM1, GM2, GD1a, GD1b and GQ1b <i>The sample analytes included will depend on their prevalence in the general population, therefore not all analytes may be covered during the year</i>								
Units for Reporting:	Results may be reported as Ratio, Titre, Other or N/A								
Samples Distributed:	Liquid format. Normal and pathological human serum								
Number of Distributions per year:	6								
Number of Samples per Distribution:	2								
Frequency of Distributions:	Every two months as outlined in the Distribution Schedule								
Schedule of Analysis:	Data entry is via the web for the submission of results. Data analysis is commenced 21 days after sample dispatch. Late returns are accepted and will contribute to the laboratory's cumulative performance statistics								
Data Analysis:	Qualitative responses are recorded for each analyte and assessed in relation to the designated response. Reports also show the number of Positive or Negative responses for each method								
Performance Scoring:	MI scoring								
Criteria of Performance:	Laboratory performance is classified in terms of OMIS derived from the qualitative responses for all analytes for which the laboratory is registered over a running analytical window of 6 Distributions (12 months) The categories of performance are: <table> <thead> <tr> <th></th> <th><u>Total MIS</u></th> </tr> </thead> <tbody> <tr> <td>Good</td> <td>zero</td> </tr> <tr> <td>Adequate</td> <td>1 - 3</td> </tr> <tr> <td>Poor</td> <td>>3</td> </tr> </tbody> </table>		<u>Total MIS</u>	Good	zero	Adequate	1 - 3	Poor	>3
	<u>Total MIS</u>								
Good	zero								
Adequate	1 - 3								
Poor	>3								
Persistent Poor Performance:	Defined as being in the Poor Performance category for two or more successive Distributions								